| Identification |
|---|
| Name |
Hydrocortisone |
| Accession Number |
DB00741
(APRD01019)
|
| Type |
small molecule |
| Groups |
approved |
| Description |
The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. [PubChem] |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- 11beta-Hydroxycortisone
- 17alpha-Hydroxycorticosterone
- Anti-inflammatory hormone
- Dihydrocostisone
- Hidrocortisona [INN-Spanish]
- Hydrocorticosterone
- Hydrocortisone Acetate
- Hydrocortisone alcohol
- Hydrocortisone Base
- Hydrocortisone Butyrate
- Hydrocortisone free alcohol
- Hydrocortisone Sodium Phosphate
- Hydrocortisone Valerate
- Hydrocortisonum [INN-Latin]
- Hydroxycortisone
- Idrocortisone [DCIT]
|
| Brand names |
- Acticort
- Aeroseb HC
- Aeroseb-HC
- Ala-cort
- Ala-Scalp
- Alacort
- Algicirtis
- Alphaderm
- Amberin
- Anflam
- Anusol HC
- Aquacort
- Aquanil HC
- Balneol-hc
- Barseb HC
- Basan-Corti
- Beta-hc
- CaldeCORT Spray
- Cetacort
- Clear aid
- Cleiton
- Cobadex
- Colocort
- Compound F
- Cort-Dome
- Cort-Quin
- Cortaid
- Cortanal
- Cortef
- Cortef Acetate
- Cortenema
- Cortesal
- Corticreme
- Cortifan
- Cortifoam
- Cortiment
- Cortisol
- Cortisol alcohol
- Cortisolonum
- Cortisporin
- Cortisporin Otico
- Cortispray
- Cortolotion
- Cortonema
- Cortoxide
- Cortril
- Cremesone
- Cremicort-H
- Cutisol
- Delacort
- Derm-Aid
- Dermacort
- Dermaspray
- Dermil
- Dermocortal
- Dermolate
- Dioderm
- Dome-cort
- Domolene-HC
- Dricort
- Drotic
- EF corlin
- Efcorbin
- Efcortelan
- Efcortelin
- Eldecort
- Eldercort
- Epicort
- Epiderm H
- Esiderm H
- Evacort
- Ficortril
- Fiocortril
- Flexicort
- Foille Insetti
- Genacort
- Glycort
- Gyno-Cortisone
- H-Cort
- Heb Cort
- Heb-Cort
- Hemsol-HC
- Hi-cor
- Hidalone
- Hidro-Colisona
- Hycort
- Hycortol
- Hycortole
- Hydracort
- Hydrasson
- Hydro-adreson
- Hydro-colisona
- Hydrocort
- Hydrocortal
- Hydrocortistab
- Hydrocortisyl
- Hydrocortone
- Hydroskin
- Hysone
- Hytisone
- Hytone
- Hytone lotion
- Incortin-H
- Incortin-hydrogen
- Kendall's compound F
- Komed HC
- Kyypakkaus
- Lacticare HC
- Lacticare-HC
- Lactisona
- Locoid
- Locoid Lipocream
- Lubricort
- Maintasone
- Medicort
- Meusicort
- Micort-hc
- Mildison
- Milliderm
- Neosporin-H Ear
- Nogenic HC
- Nutracort
- Nystaform-HC
- Optef
- Orabase HCA
- Otalgine
- Otobiotic
- Otocort
- Otosone-F
- Pandel
- Pediotic Suspension
- Penecort
- Permicort
- Polcort H
- Preparation H Hydrocortisone Cream
- Prepcort
- Prevex HC
- Proctocort
- Proctofoam
- Protocort
- Racet
- Rectoid
- Reichstein's Substance M
- Remederm HC
- Sanatison
- Scalpicin Capilar
- Schericur
- Scheroson F
- Sigmacort
- Signef
- Stie-cort
- Stiefcorcil
- Synacort
- Systral Hydrocort
- Tarcortin
- Tetrahydro E
- Tetrahydrocompound E
- Texacort
- Texacort lotion 25
- THE
- Thyrotropic-releasing factor
- Timocort
- Transderma H
- Traumaide
- Uniderm
- Urocortisone
- Vioform-Hydrocortisone
- VoSol HC
- Vytone
- Westcort
- Zenoxone
|
| Brand name mixtures |
- Actinac Pwr (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
- Actinac Pws (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
- Calmurid Hc Crm (Hydrocortisone + Urea)
- Cortisporin (Bacitracin Zinc + Hydrocortisone + Neomycin Sulfate + Polymyxin B Sulfate)
- Eye and Wound Powder (Chlorhexidine Hydrochloride + Hydrocortisone Acetate + Penicillin G Procaine + Sulfathiazole)
- Forte Topical Suspension (Hydrocortisone Acetate + Hydrocortisone Sodium Succinate + Neomycin (Neomycin Sulfate) + Penicillin G Procaine + Polymyxin B Sulfate)
- Neo-Cortef Eye Ear Dps (Hydrocortisone Acetate + Neomycin Sulfate)
- Neo-Cortef Eye Ear Drops Sterile Suspension (Hydrocortisone Acetate + Neomycin Sulfate)
- Neo-Cortef Eye Ear Ont (Hydrocortisone Acetate + Neomycin Sulfate)
- Ophthocort Ont (Chloramphenicol + Hydrocortisone Acetate + Polymyxin B (Polymyxin B Sulfate))
- Otizol Hc Liq (Hydrocortisone (Hydrocortisone Acetate) + Lidocaine (Lidocaine Hydrochloride) + Neomycin (Neomycin Sulfate))
- Proctosedyl Ointment (Dibucaine Hydrochloride + Esculin + Framycetin Sulfate + Hydrocortisone)
- Proctosedyl Sup (Dibucaine Hydrochloride + Esculin + Framycetin Sulfate + Hydrocortisone)
- Proctosedyl Suppositories (Dibucaine Hydrochloride + Esculin + Framycetin Sulfate + Hydrocortisone)
- Proctosone Ont (Dibucaine Hydrochloride + Esculin + Hydrocortisone Acetate + Neomycin Sulfate)
- Proctosone Sup (Dibucaine Hydrochloride + Esculin + Hydrocortisone Acetate + Neomycin Sulfate)
- Sopamycetin/Hc Ointment (Chloramphenicol + Hydrocortisone Acetate)
- Sopamycetin/Hc Ont (Chloramphenicol + Hydrocortisone Acetate)
- Sopamycetin/Hc Susp (Chloramphenicol + Hydrocortisone Acetate)
- Ti-U-Lac Hc Lotion (Hydrocortisone + Urea)
- Vioform + Hydrocortisone (Clioquinol + Hydrocortisone)
- Vioform Hydrocortisone Cream (Clioquinol + Hydrocortisone)
- Vioform Hydrocortisone Mild (Clioquinol + Hydrocortisone)
- Vosol Hc (Acetic Acid + Benzethonium Chloride + Hydrocortisone + Propylene Glycol Diacetate)
|
| Categories |
|
| CAS number |
50-23-7 |
| Weight |
Average: 362.4599
Monoisotopic: 362.209324070
|
| Chemical Formula |
C21H30O5 |
| InChI Key |
InChIKey=JYGXADMDTFJGBT-VWUMJDOOSA-N |
| InChI |
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
Plain Text
|
| IUPAC Name |
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one
|
| SMILES |
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Plain Text
|
| Mass Spec |
show (3 KB)
|
| Taxonomy |
|---|
| Kingdom |
Organic |
| Classes |
- Steroids and Steroid Derivatives
|
| Substructures |
- Steroids and Steroid Derivatives
- Hydroxy Compounds
- Alkanes and Alkenes
- Alcohols and Polyols
- Cyclohexenes and Derivatives
- Ketones
|
| Pharmacology |
|---|
| Indication |
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease. |
| Pharmacodynamics |
Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated. |
| Mechanism of action |
Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. |
| Absorption |
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. |
| Volume of distribution |
Not Available |
| Protein binding |
95% |
| Metabolism |
Primarily hepatic via CYP3A4
| Enzyme |
Metabolite |
Reaction |
Km |
Vmax |
|
Cytochrome P450 3A4
|
6-beta-hydrocortisol |
6-beta-hydroxylation |
15.2 |
0.0064 |
|
| Route of elimination |
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. |
| Half life |
6-8 hours |
| Clearance |
Not Available |
| Toxicity |
Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing |
| Affected organisms |
|
| Pathways |
Not Available |
| Pharmacoeconomics |
|---|
| Manufacturers |
- Hi tech pharmacal co inc
- Allergan herbert div allergan inc
- Del ray laboratories inc
- Salix pharmaceuticals inc
- Bayer pharmaceuticals corp
- Monarch pharmaceuticals inc
- Valeant pharmaceuticals international
- Westwood squibb pharmaceuticals inc
- C and m pharmacal inc
- Pharmaceutical assoc inc div beach products
- Actavis mid atlantic llc
- Alpharma us pharmaceuticals division
- Altana inc
- Ambix laboratories div organics corp america
- Everylife
- E fougera div altana inc
- G and w laboratories inc
- Ingram pharmaceutical co
- Ivax pharmaceuticals inc
- Naska pharmacal co inc div rugby darby group cosmetics
- Perrigo new york inc
- Pharmaderm div altana inc
- Pharmafair inc
- Stiefel laboratories inc
- Syosset laboratories inc
- Taro pharmaceuticals usa inc
- Teva pharmaceuticals usa inc
- Topiderm inc
- Usl pharma inc
- Vintage pharmaceuticals inc
- Whiteworth towne paulsen inc
- Sanofi aventis us llc
- Coria laboratories ltd
- Medicis pharmaceutical corp
- Paddock laboratories inc
- Ani pharmaceuticals inc
- Teva pharmaceuticals usa
- Healthpoint ltd
- Allergan herbert skin care div allergan inc
- Pharmacia and upjohn co
- Baker norton pharmaceuticals inc
- Solvay pharmaceuticals
- Beta dermaceuticals inc
- Bluline laboratories inc
- Heran pharmaceutical inc
- Mericon industries inc
- Perrigo co
- Pfizer global research development
- Carolina medical products co
- Dermik laboratories div aventis pharmaceuticals inc
- Torch laboratories inc
- X gen pharmaceuticals inc
- Jsj pharmaceuticals llc
- Pfizer laboratories div pfizer inc
- Barr laboratories inc
- Elkins sinn div ah robins co inc
- John j ferrante
- Impax laboratories inc
- Inwood laboratories inc sub forest laboratories inc
- Lannett co inc
- Nexgen pharma inc
- Panray corp sub ormont drug and chemical co inc
- Parke davis div warner lambert co
- Purepac pharmaceutical co
- Roxane laboratories inc
- Sandoz inc
- Stiefel a gsk co
- Vintage pharmaceuticals llc
- Watson laboratories inc
- West ward pharmaceutical corp
- Merck and co inc
- Pfipharmecs div pfizer inc
- Schwarz pharma inc
- Able laboratories inc
- Hr cenci laboratories inc
- Ferndale laboratories inc
- Akorn inc
- Bel mar laboratories inc
- Colgate oral pharmaceuticals inc
- Taro pharmaceutical industries ltd
- Triax pharmaceuticals llc
- Yamanouchi europe bv
- Savage laboratories inc div altana inc
- Abbott laboratories pharmaceutical products div
- Abbott laboratories hosp products div
- Hospira inc
- Abraxis pharmaceutical products
- Baxter healthcare corp anesthesia and critical care
- International medication systems ltd
- Taro pharmaceuticals inc
- Ranbaxy laboratories inc
|
| Packagers |
|
| Dosage forms |
| Form |
Route |
Strength |
| Aerosol |
Rectal |
|
| Cream |
Topical |
|
| Enema |
Rectal |
|
| Liquid |
Topical |
|
| Lotion |
Topical |
|
| Ointment |
Ophthalmic |
|
| Ointment |
Topical |
|
| Powder, for solution |
Intramuscular |
|
| Powder, for solution |
Intravenous |
|
| Tablet |
Oral |
|
|
| Prices |
| Unit description |
Cost |
Unit |
| Locoid Lipocream 0.1% Cream 60 gm Tube |
335.36 USD |
tube |
| Cortifoam 90 mg Foam 15 gm Can |
239.99 USD |
can |
| Locoid 0.1% Solution 60ml Bottle |
233.15 USD |
bottle |
| Locoid Lipocream 0.1% Cream 45 gm Tube |
200.98 USD |
tube |
| Locoid 0.1% Cream 45 gm Tube |
183.83 USD |
tube |
| Locoid 0.1% Ointment 45 gm Tube |
174.86 USD |
tube |
| Pandel 0.1% Cream 45 gm Tube |
161.37 USD |
tube |
| Pandel 0.1% Cream 15 gm Tube |
138.56 USD |
tube |
| Proctocort 1% Cream 28.35 gm Tube |
127.51 USD |
tube |
| Anusol-HC 2.5% Cream 30 gm Tube |
106.45 USD |
tube |
| Locoid Lipocream 0.1% Cream 15 gm Tube |
85.41 USD |
tube |
| Texacort 2.5% Solution 30ml Bottle |
85.41 USD |
bottle |
| Cortisporin 3.5-10000-1 Solution 10ml Bottle |
84.33 USD |
bottle |
| Proctofoam HC 1-1% Foam 10 gm Can |
81.9 USD |
can |
| Cortisporin 3.5-10000-1 Suspension 10ml Bottle |
79.55 USD |
bottle |
| Locoid 0.1% Solution 20ml Bottle |
79.28 USD |
bottle |
| Cortisporin 1% Ointment 15 gm Tube |
75.09 USD |
tube |
| Locoid 0.1% Cream 15 gm Tube |
67.49 USD |
tube |
| Hydrocortisone Ace-Pramoxine 2.5-1% Cream 28.35 gm Tube |
64.75 USD |
tube |
| Locoid 0.1% Ointment 15 gm Tube |
62.04 USD |
tube |
| Hydrocortisone Valerate 0.2% Ointment 60 gm Tube |
56.74 USD |
tube |
| Hydrocortisone 2.5% Lotion 59 gm Bottle |
55.61 USD |
bottle |
| Westcort 0.2% Ointment 60 gm Tube |
55.0 USD |
tube |
| Cortisporin 0.5-0.5-10000 Cream 7.5 gm Tube |
54.37 USD |
tube |
| Westcort 0.2% Ointment 15 gm Tube |
50.99 USD |
tube |
| Hydrocortisone Butyrate 0.1% Cream 45 gm Tube |
49.43 USD |
tube |
| Hydrocortisone Valerate 0.2% Ointment 45 gm Tube |
48.73 USD |
tube |
| Hydrocortisone 2.5% Lotion 59ml Bottle |
47.47 USD |
bottle |
| Westcort 0.2% Ointment 45 gm Tube |
46.97 USD |
tube |
| Hydrocortisone Valerate 0.2% Cream 60 gm Tube |
44.99 USD |
tube |
| Hydrocortisone Valerate 0.2% Cream 45 gm Tube |
33.99 USD |
tube |
| Ala Scalp 2% Lotion 29.6ml Bottle |
30.99 USD |
bottle |
| Hydrocortisone Valerate 0.2% Ointment 15 gm Tube |
30.56 USD |
tube |
| Westcort 0.2% Cream 15 gm Tube |
25.99 USD |
tube |
| Hydrocortisone Valerate 0.2% Cream 15 gm Tube |
19.99 USD |
tube |
| Cortisporin eye drops |
19.74 USD |
ml |
| Solu-Cortef 1 g/vial |
17.55 USD |
vial |
| Hydrocortisone 1% Lotion 118ml Bottle |
15.99 USD |
bottle |
| Hydrocortisone Acetate 12 25 mg Suppository Box |
15.01 USD |
box |
| Hydrocortisone 2.5% Ointment 28.35 gm Tube |
13.68 USD |
tube |
| Hydrocortisone 2.5% Cream 30 gm Tube |
13.67 USD |
tube |
| Colocort 100 mg/60ml Enema 60ml Bottle |
13.15 USD |
bottle |
| Hydrocortisone 100 mg/60ml Enema 60ml Bottle |
12.6 USD |
bottle |
| Hydrocortisone 0.5% Cream 28.35 gm Tube |
11.99 USD |
tube |
| Hydrocortisone 1% Cream 15 gm Tube |
11.99 USD |
tube |
| Hydrocortisone 1% Cream 28 gm Tube |
11.99 USD |
tube |
| Hydrocortisone Acetate 1-1% Ointment 30 gm Tube |
11.99 USD |
tube |
| Solu-Cortef 500 mg/vial |
10.47 USD |
vial |
| Hydrocortisone hemisucc powder |
9.9 USD |
g |
| Cortifoam 10% aerosol |
9.35 USD |
g |
| Hydrocortisone Sod. Succinate 1 g/vial |
9.01 USD |
vial |
| Solu-cortef (pf) 250 mg vial |
8.58 USD |
vial |
| Cortisporin-tc ear susp |
8.3 USD |
ml |
| Cortisporin ear suspension |
7.86 USD |
ml |
| Solu-Cortef 250 mg/vial |
7.05 USD |
vial |
| Cortenema (100 mg/60Ml) 100 mg/enm Enema |
6.96 USD |
enema |
| Proctofoam-hc foam |
6.77 USD |
g |
| Cortifoam 10 % Foam |
6.14 USD |
g |
| Hycort (100 mg/60Ml) 100 mg/enm Enema |
5.79 USD |
enema |
| Cortamed 2.5 % Ointment |
5.67 USD |
g |
| Hydrocortisone Sod. Succinate 500 mg/vial |
5.34 USD |
vial |
| Hydrocortisone powder |
5.19 USD |
g |
| Solu-cortef (pf) 100 mg vial |
4.85 USD |
vial |
| Solu-cortef 100 mg vial |
4.63 USD |
vial |
| Proctocort 1% cream |
4.37 USD |
g |
| Pandel 0.1% cream |
4.34 USD |
g |
| Locoid 0.1% lipocream |
4.3 USD |
g |
| Solu-Cortef 100 mg/vial |
4.07 USD |
vial |
| Locoid 0.1% cream |
3.92 USD |
g |
| Hydrocortisone Sod. Succinate 250 mg/vial |
3.56 USD |
vial |
| Hydrocortisone ss 250 mg vial |
3.5 USD |
vial |
| Anusol-hc 2.5% cream |
3.45 USD |
g |
| Hydrocortisone acet powder |
3.15 USD |
g |
| Proctofoam |
2.89 USD |
g |
| A-hydrocort 100 mg vial |
2.42 USD |
each |
| Proctocream-hc 2.5% cream |
2.17 USD |
g |
| Hydrocortisone Sod. Succinate 100 mg/vial |
2.1 USD |
vial |
| Hydrocortisone val 0.2% cream |
2.07 USD |
g |
| Hytone 2.5% cream |
1.46 USD |
g |
| Hydrocortisone buty 0.1% cream |
1.31 USD |
g |
| First hydrocort 10% gel |
1.18 USD |
g |
| Westcort 0.2% cream |
1.17 USD |
g |
| Procto-kit 1% cream |
1.08 USD |
g |
| Ala-scalp hp 2% lotion |
1.03 USD |
ml |
| Cortef 20 mg tablet |
0.9 USD |
tablet |
| Proctosol-hc 2.5% cream |
0.89 USD |
g |
| Proctozone-hc 2.5% cream |
0.83 USD |
g |
| Orabase plain paste |
0.77 USD |
g |
| Hydrocortisone 2.5% lotion |
0.6 USD |
ml |
| Cortef 10 mg tablet |
0.55 USD |
tablet |
| Orabase-b 20% gel |
0.55 USD |
g |
| Hydrocortisone 2.5% cream |
0.53 USD |
g |
| Hydrocortisone 10 mg tablet |
0.52 USD |
tablet |
| Cortef 5 mg tablet |
0.45 USD |
tablet |
| Ala-cort 1% cream |
0.43 USD |
g |
| Hydrocortisone 5 mg tablet |
0.38 USD |
tablet |
| Corticaine 0.5% cream |
0.37 USD |
g |
| Hydrocortisone 20 mg tablet |
0.32 USD |
tablet |
| Prevex Hc 1 % Occlusive Cream |
0.3 USD |
g |
| Emo-Cort 2.5 % Cream |
0.26 USD |
g |
| Preparation h 1% cream |
0.24 USD |
g |
| Tucks hydrocortisone ointment |
0.24 USD |
g |
| Emo-Cort 2.5 % Lotion |
0.23 USD |
g |
| Emo-Cort Scalp 2.5 % Lotion |
0.22 USD |
g |
| Colocort 100 mg enema |
0.21 USD |
ml |
| Cortenema 100 mg enema |
0.21 USD |
ml |
| Sarna Hc 2.5 % Lotion |
0.2 USD |
g |
| Emo-Cort 1 % Cream |
0.19 USD |
g |
| Balneol lotion |
0.18 USD |
ml |
| Emo-Cort 1 % Lotion |
0.18 USD |
g |
| Lanacort 1% cool creme |
0.18 USD |
g |
| Hyderm 0.5 % Cream |
0.18 USD |
g |
| Hytone 1% cream |
0.17 USD |
g |
| Cortoderm Mild 0.5 % Ointment |
0.15 USD |
g |
| Beta hc 1% lotion |
0.14 USD |
ml |
| Cortizone-10 1% spray |
0.14 USD |
ml |
| Hydroval 0.2 % Cream |
0.13 USD |
g |
| Hydroval 0.2 % Ointment |
0.13 USD |
g |
| Aquanil hc 1% lotion |
0.12 USD |
ml |
| Hydrocortisone plus 12 1% crm |
0.12 USD |
g |
| Scalpicin 3% liquid |
0.12 USD |
ml |
| Slender cortisol capsule |
0.12 USD |
capsule |
| Cortaid 1% spray |
0.1 USD |
ml |
| Sarna Hc 1 % Lotion |
0.1 USD |
g |
| Hydrocortisone 0.5% cream |
0.08 USD |
g |
| Hydrocortisone 1% cream |
0.08 USD |
g |
| Uniderm moisturizer |
0.05 USD |
ml |
| Cortoderm Regular 1 % Ointment |
0.04 USD |
g |
| Hyderm 1 % Cream |
0.04 USD |
g |
|
| Patents |
| Country |
Patent Number |
Approved |
Expires |
| United States |
7378405 |
2006-12-19 |
2026-12-19 |
| United States |
5635497 |
1994-06-03 |
2014-06-03 |
|
| Properties |
|---|
| State |
solid |
| Melting point |
220 oC |
| Experimental Properties |
| Property |
Value |
Source |
| water solubility |
320 mg/L |
PhysProp |
| logP |
1.61 [HANSCH,C ET AL. (1995)] |
PhysProp |
| logS |
-2.97 [ADME Research, USCD] |
PhysProp |
| Caco2 permeability |
-4.66 [ADME Research, USCD] |
BiGG |
|
| Predicted Properties |
|
| References |
|---|
| Synthesis Reference |
Not Available
|
| General Reference |
- de Weerth C, Zijl RH, Buitelaar JK: Development of cortisol circadian rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52. Pubmed
- Palacios R, Sugawara I: Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol. 1982 Jan;15(1):25-31. Pubmed
- KNIGHT RP Jr, KORNFELD DS, GLASER GH, BONDY PK: Effects of intravenous hydrocortisone on electrolytes of serum and urine in man. J Clin Endocrinol Metab. 1955 Feb;15(2):176-81. Pubmed
|
| External Links |
|
| ATC Codes |
- A01AC03
- A07EA02
- C05AA01
- D07AA02
- D07AB02
- D07AB11
- D07AC16
- D07XA01
- H02AB09
- S01BA02
- S01CB03
- S02BA01
|
| AHFS Codes |
- 52:08.08
- 84:06.00
- 68:04.00
|
| PDB Entries |
Not Available |
| FDA label |
show (30 KB)
|
| MSDS |
show (73.6 KB)
|
| Interactions |
|---|
| Drug Interactions |
Not Available |
| Food Interactions |
- Take with food to reduce irritation. Calcium, phosphorous, potassium, Vitamin A, C, D and zinc needs increased with long term use.
|
| Targets |
|---|
1. Glucocorticoid receptor
Pharmacological action: yes
Actions: agonist
Receptor for glucocorticoids (GC). Has a dual mode of action:as a transcription factor that binds to glucocorticoid response elements (GRE) and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth
Organism class: human
UniProt ID: P04150 
Gene: NR3C1
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. Pubmed
- Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. Pubmed
- Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. Pubmed
- Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. Pubmed
- Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. Pubmed
2. Annexin A1
Pharmacological action: yes
Actions: agonist
Calcium/phospholipid-binding protein which promotes membrane fusion and is involved in exocytosis. This protein regulates phospholipase A2 activity. It seems to bind from two to four calcium ions with high affinity
Organism class: human
UniProt ID: P04083
Gene: ANXA1
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
- Sato-Matsumura KC, Matsumura T, Nakamura H, Sawa H, Nagashima K, Koizumi H: Membrane expression of annexin I is enhanced by calcium and TPA in cultured human keratinocytes. Arch Dermatol Res. 2000 Oct;292(10):496-9. Pubmed
- White MV, Igarashi Y, Lundgren JD, Shelhamer J, Kaliner M: Hydrocortisone inhibits rat basophilic leukemia cell mediator release induced by neutrophil-derived histamine releasing activity as well as by anti-IgE. J Immunol. 1991 Jul 15;147(2):667-73. Pubmed
- Serres M, Viac J, Comera C, Schmitt D: Expression of annexin I in freshly isolated human epidermal cells and in cultured keratinocytes. Arch Dermatol Res. 1994;286(5):268-72. Pubmed
|
| Enzymes |
|---|
1. Cytochrome P450 3A4
Actions: substrate, inhibitor
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4- hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. The enzyme also hydroxylates etoposide
UniProt ID: P08684
Gene: CYP3A4
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
- Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. Pubmed
2. Cytochrome P450 3A5
Actions: substrate
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics
UniProt ID: P20815
Gene: CYP3A5
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
3. Cytochrome P450 3A7
Actions: substrate
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics
UniProt ID: P24462
Gene: CYP3A7
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
4. Cytochrome P450 11B1, mitochondrial
Actions: substrate
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB
UniProt ID: P15538
Gene: CYP11B1
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
5. Cytochrome P450 11B2, mitochondrial
Actions: substrate
Preferentially catalyzes the conversion of 11- deoxycorticosterone to aldosterone via corticosterone and 18- hydroxycorticosterone
UniProt ID: P19099
Gene: CYP11B2
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
6. Cytochrome P450 2C8
Actions: inducer
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti- cancer drug paclitaxel (taxol)
UniProt ID: P10632
Gene: CYP2C8
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
|
| Transporters |
|---|
1. Multidrug resistance protein 1
Actions: substrate, inhibitor
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells
UniProt ID: P08183
Gene: ABCB1
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. Pubmed
- Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. Pubmed
- Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. Pubmed
- Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. Pubmed
- Orlowski S, Mir LM, Belehradek J Jr, Garrigos M: Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J. 1996 Jul 15;317 ( Pt 2):515-22. Pubmed
2. ATP-binding cassette sub-family G member 2
Actions: inhibitor
Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. May be involved in brain-to-blood efflux. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. When overexpressed, the transfected cells become resistant to mitoxantrone, daunorubicin and doxorubicin, display diminished intracellular accumulation of daunorubicin, and manifest an ATP- dependent increase in the efflux of rhodamine 123
UniProt ID: Q9UNQ0
Gene: ABCG2
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. Pubmed
3. Solute carrier organic anion transporter family member 1A2
Actions: inhibitor
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity)
UniProt ID: P46721
Gene: SLCO1A2
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. Pubmed
- Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. Pubmed
|
| Carriers |
|---|
1. Sex hormone-binding globulin
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration
UniProt ID: P04278
Gene: SHBG
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report
References:
- Khoromi S, Muniyappa R, Nackers L, Gray N, Baldwin H, Wong KA, Matheny LA, Moquin B, Rainer A, Hill S, Remaley A, Johnson LL, Max MB, Blackman MR: Effects of chronic osteoarthritis pain on neuroendocrine function in men. J Clin Endocrinol Metab. 2006 Nov;91(11):4313-8. Epub 2006 Aug 15. Pubmed
- Stroud LR, Solomon C, Shenassa E, Papandonatos G, Niaura R, Lipsitt LP, Lewinn K, Buka SL: Long-term stability of maternal prenatal steroid hormones from the National Collaborative Perinatal Project: still valid after all these years. Psychoneuroendocrinology. 2007 Feb;32(2):140-50. Epub 2007 Jan 31. Pubmed
- Lombardi G, Mondaini N, Macchiarella A, Del Popolo G: Female sexual dysfunction and hormonal status in spinal cord injured (SCI) patients. J Androl. 2007 Sep-Oct;28(5):722-6. Epub 2007 May 9. Pubmed
- Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA: A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007 May 15;. Pubmed
- Rizzo L, Dobrovsky V, Danilowicz K, Kral M, Cross G, Serra HA, Bruno OD: Low-dose glucocorticoids in hyperandrogenism. Medicina (B Aires). 2007;67(3):247-52. Pubmed
|
